Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...